Potential impact of high-density lipoprotein cholesterol in the postoperative outcomes of chronic subdural hematoma patients: multi-institutional study in Korea.
Burr hole trephination
Cholesterol
Chronic subdural hematoma
Statin
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
18
08
2023
accepted:
13
11
2023
medline:
20
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
Chronic subdural hematoma (CSDH) is a common clinical situation in neurosurgical practice, but the optimal treatment option is controversial. This study aimed to evaluate the effect of cholesterol-lowering medications on and how they affected the prognoses of CSDH patients. In this multi-institutional observational study performed in Korea, data from recently treated CSDH patients were gathered from 5 hospitals. A total of 462 patients were collected from March 2010 to June 2021. Patient clinical characteristics, history of underlying diseases and their treatments, radiologic features, and surgical outcomes were analyzed. Seventy-five patients experienced recurrences, and 62 had reoperations after the initial burr hole surgery. Among these, 15 patients with recurrences and 12 with reoperations were taking cholesterol-lowering medications. However, the use of medications did not significantly affect recurrence or reoperation rates (P = 0.350, P = 0.336, respectively). When analyzed by type of medication, no clinically relevant differences in total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C) levels were identified. The combination of a statin drug and ezetimibe significantly elevated high-density lipoprotein cholesterol (HDL-C) levels (P = 0.004). TC, LDL-C, and TG levels did not significantly affect patient prognoses. However, HDL-C levels and recurrence (odds ratio (OR) = 0.96; 95% confidence interval (CI): 0.94-0.99; p = 0.010) were negatively correlated. An HDL-C level of 42.50 mg/dL was identified as the threshold for recurrence and reoperation. In this study, using cholesterol-lowering medications did not significantly impact the prognosis of patients who underwent surgical management for a chronic subdural hematoma. However, the findings showed that the higher the HDL-C level, the lower the probability of recurrence and reoperation.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic subdural hematoma (CSDH) is a common clinical situation in neurosurgical practice, but the optimal treatment option is controversial. This study aimed to evaluate the effect of cholesterol-lowering medications on and how they affected the prognoses of CSDH patients.
METHODS
METHODS
In this multi-institutional observational study performed in Korea, data from recently treated CSDH patients were gathered from 5 hospitals. A total of 462 patients were collected from March 2010 to June 2021. Patient clinical characteristics, history of underlying diseases and their treatments, radiologic features, and surgical outcomes were analyzed.
RESULTS
RESULTS
Seventy-five patients experienced recurrences, and 62 had reoperations after the initial burr hole surgery. Among these, 15 patients with recurrences and 12 with reoperations were taking cholesterol-lowering medications. However, the use of medications did not significantly affect recurrence or reoperation rates (P = 0.350, P = 0.336, respectively). When analyzed by type of medication, no clinically relevant differences in total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C) levels were identified. The combination of a statin drug and ezetimibe significantly elevated high-density lipoprotein cholesterol (HDL-C) levels (P = 0.004). TC, LDL-C, and TG levels did not significantly affect patient prognoses. However, HDL-C levels and recurrence (odds ratio (OR) = 0.96; 95% confidence interval (CI): 0.94-0.99; p = 0.010) were negatively correlated. An HDL-C level of 42.50 mg/dL was identified as the threshold for recurrence and reoperation.
CONCLUSIONS
CONCLUSIONS
In this study, using cholesterol-lowering medications did not significantly impact the prognosis of patients who underwent surgical management for a chronic subdural hematoma. However, the findings showed that the higher the HDL-C level, the lower the probability of recurrence and reoperation.
Identifiants
pubmed: 37978499
doi: 10.1186/s12944-023-01970-5
pii: 10.1186/s12944-023-01970-5
pmc: PMC10655259
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197Informations de copyright
© 2023. The Author(s).
Références
Acta Neurochir (Wien). 2021 Apr;163(4):1061-1068
pubmed: 33146806
World Neurosurg. 2018 Aug;116:402-411.e2
pubmed: 29772364
Surg Neurol. 2007 Apr;67(4):367-72; discussion 372-3
pubmed: 17350403
Am J Med Sci. 2012 Sep;344(3):220-6
pubmed: 22475732
Br J Pharmacol. 2015 Nov;172(21):5188-98
pubmed: 26289767
Biomed Pharmacother. 2010 Jan;64(1):29-34
pubmed: 19811885
World Neurosurg. 2021 May;149:e281-e291
pubmed: 33610873
Cardiovasc Res. 2015 May 1;106(2):184-93
pubmed: 25759067
Curr Opin Lipidol. 2021 Oct 1;32(5):315-322
pubmed: 34374677
World Neurosurg. 2018 Sep;117:e425-e429
pubmed: 29920396
JAMA Neurol. 2018 Nov 1;75(11):1338-1346
pubmed: 30073290
J Neurosurg. 2001 Aug;95(2):256-62
pubmed: 11780895
Medicine (Baltimore). 2017 Jun;96(26):e7290
pubmed: 28658127
Neurol Med Chir (Tokyo). 2001 Aug;41(8):371-81
pubmed: 11561347
J Neurosurg. 2003 Jun;98(6):1217-21
pubmed: 12816267
J Neurotrauma. 2014 Apr 1;31(7):670-3
pubmed: 24245657
Int J Biol Macromol. 2022 Jan 15;195:117-123
pubmed: 34896462
Can J Neurol Sci. 2015 Jan;42(1):34-9
pubmed: 25557536
Eur J Neurol. 2012 Dec;19(12):1539-46
pubmed: 22640405
Metabolism. 2015 Nov;64(11):1466-76
pubmed: 26347012
Acta Neurochir (Wien). 2021 Jul;163(7):1843-1848
pubmed: 34036461
Lancet. 2009 Sep 26;374(9695):1067-73
pubmed: 19782872
Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38
pubmed: 18553127
World Neurosurg. 2016 Jul;91:23-8
pubmed: 27044372
Angiogenesis. 2018 May;21(2):381-394
pubmed: 29450744
J Neurointerv Surg. 2021 Oct;13(10):951-957
pubmed: 34193592
World Neurosurg. 2019 Feb;122:613-619
pubmed: 30481628
Expert Opin Pharmacother. 2020 Mar;21(4):435-444
pubmed: 31957506
Atherosclerosis. 2017 May;260:27-33
pubmed: 28340366
Diagnostics (Basel). 2022 Nov 14;12(11):
pubmed: 36428849
J Neurochem. 2007 Aug;102(4):1001-8
pubmed: 17442054
Br J Neurosurg. 2017 Feb;31(1):72-77
pubmed: 27881024
Neurosurg Rev. 2021 Feb;44(1):479-484
pubmed: 31953781
J Neurol Sci. 2016 Mar 15;362:91-9
pubmed: 26944125
Drug Des Devel Ther. 2020 Aug 12;14:3291-3299
pubmed: 32848367
J Neurol Sci. 2014 Jun 15;341(1-2):88-96
pubmed: 24774750